ImmunityBio Investors Urged to Act Before May 2026 Securities Class Action Deadline Investors of ImmunityBio are reminded about the upcoming deadline for a class action lawsuit on May 26, 2026, regarding potential financial claims.

ImmunityBio Investors Urged to Act Before May 2026 Securities Class Action Deadline #United_States #New_York #Faruqi_&_Faruqi #ImmunityBio #IBRX

ImmunityBio Faces Securities Class Action Deadline ImmunityBio (IBRX) investors urged to secure counsel after Rosen Law filed a class action on Mar 28, 2026; lead-plaintiff motions are typically due within 60 days.

ImmunityBio Faces Securities Class Action Deadline: ImmunityBio (IBRX) investors urged to secure counsel after Rosen Law filed a class action on Mar 28, 2026; lead-plaintiff motions are typically due… 👈 Read full analysis #ImmunityBio #SecuritiesClassAction #Investors #LegalCounsel #StockMarket

Investors in ImmunityBio Have a Chance to Lead a Significant Class Action Lawsuit Rosen Law Firm has initiated a class action lawsuit on behalf of ImmunityBio investors. Affected shareholders may be eligible for compensation. Act before the deadline!

Investors in ImmunityBio Have a Chance to Lead a Significant Class Action Lawsuit #USA #New_York #Rosen_Law_Firm #ImmunityBio #IBRX

Class Action Alert: ImmunityBio Inc. Investors Can Lead Major Lawsuit Investors of ImmunityBio, Inc. facing significant losses have a valuable opportunity to become the lead plaintiff in a class action lawsuit against the company.

Class Action Alert: ImmunityBio Inc. Investors Can Lead Major Lawsuit #USA #San_Diego #Class_Action #ImmunityBio #IBRX

Pomerantz Law Firm Investigates Potential Securities Fraud Claims Against ImmunityBio, Inc. and Its Directors Investors in ImmunityBio, Inc. are urged to contact Pomerantz LLP regarding potential claims of securities fraud and unlawful practices.

Pomerantz Law Firm Investigates Potential Securities Fraud Claims Against ImmunityBio, Inc. and Its Directors #United_States #New_York #Pomerantz #ImmunityBio #IBRX

ImmunityBio warned by FDA over 'misleading' Anktiva content The FDA has sent a warning letter to ImmunityBio over "false and misleading" comments made by executive chair, billionaire Patrick Soon-Shiong

The FDA has sent a warning letter to #ImmunityBio over "false and misleading" comments made by executive chair, billionaire Patrick Soon-Shiong, about bladder cancer drug Anktiva.

FDA slams Soon-Shiong and ImmunityBio for making 'false and misleading' claims about a drug Patrick Soon-Shiong, a controversial figure in the biotech industry, was accused by the FDA of making false and misleading claims about a cancer treatment.

FDA slams Soon-Shiong and ImmunityBio for making ‘false and misleading’ claims about a drug.. statnews.com/pharmalot/20... #pharma #FDA #misleading #ImmunityBio #cancer #soonshiong

ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded Anktiva® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally - ImmunityBio

ImmunityBio reports ~700% year-over-year revenue growth for ANKTIVA®, backed by expanded approvals across lung and bladder cancer indications in 33 countries; a major commercial and treatment milestone. #CancerTherapy #ImmunityBio #CancerCare #TCSC
immunitybio.com/immunitybio-...

Pomerantz Law Firm Launches Investigation into ImmunityBio, Inc. for Potential Securities Fraud Pomerantz Law Firm is probing potential securities fraud involving ImmunityBio, Inc. (IBRX) following significant stock price decline after clinical results announcement.

Pomerantz Law Firm Launches Investigation into ImmunityBio, Inc. for Potential Securities Fraud #United_States #New_York #Pomerantz #ImmunityBio #IBRX

Pomerantz Law Firm Investigates Potential Securities Fraud at ImmunityBio, Inc. Amidst Recent Stock Drop Pomerantz LLP is probing potential claims against ImmunityBio, Inc. following a significant stock drop related to clinical trial results. Investors may have legal options.

Pomerantz Law Firm Investigates Potential Securities Fraud at ImmunityBio, Inc. Amidst Recent Stock Drop #USA #New_York #Pomerantz_LLP #ImmunityBio #IBRX

Investor Alert: Pomerantz Law Firm Investigates ImmunityBio on Behalf of Investors Following Recent Press Release Pomerantz LLP is probing potential securities fraud claims against ImmunityBio, Inc. after recent press release about clinical trials led to share price drop.

Investor Alert: Pomerantz Law Firm Investigates ImmunityBio on Behalf of Investors Following Recent Press Release #USA #New_York #Pomerantz_LLP #ImmunityBio #IBRX

Shares in #ImmunityBio rose sharply after the company said it has agreed a path with the #FDA that will allow it to refile for approval of wider use of its #bladdercancer therapy, #Anktiva, in papillary-only disease.

pharmaphorum.com/news/immunit...

⚡️ #ImmunityBio annonce une réponse complète et durable de 15 mois avec une thérapie cellulaire #CAR_T 🧬 #NK ☠️ #CD19 sans chimiothérapie dans le #Lymphome de Waldenström
www.businesswire.com/news/home/20...

U.S.-Saudi Biotech Alliance Summit Kicks Off in San Francisco Today The inaugural U.S.-Saudi Biotech Alliance Summit starts today in San Francisco, aiming to boost biomanufacturing and medical readiness.

U.S.-Saudi Biotech Alliance Summit Kicks Off in San Francisco Today #USA #San_Francisco #NYSE #ImmunityBio #Biotech_Summit

www.businesswire.com/news/home/20... #Immunitybio #LungCancer #IBRX

Pat Soon-Shiong: Solving the Global BCG Shortage with ImmunityBio’s Supercharged BCG - OncoDaily Pat Soon-Shiong: Solving the Global BCG Shortage with ImmunityBio’s Supercharged BCG / BCG, cancer, ImmunityBio, OncoDaily, Oncology, Pat Soon-Shiong, UroToday

Solving the Global BCG Shortage with ImmunityBio’s Supercharged BCG - Pat Soon-Shiong

oncodaily.com/voices/pat-s...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BCG #ImmunityBio

FDA Implements Stricter Survival Guidelines Amid Expanding Oncology Investment Landscape The FDA has introduced stricter survival standards in cancer treatments, while private investments surge in the oncology sector, reaching an $866 billion market.

FDA Implements Stricter Survival Guidelines Amid Expanding Oncology Investment Landscape #Vancouver #Cancer_Research #Oncolytics_Biotech #ImmunityBio

Facing Cuts in Public Cancer Funding, Private Sector Takes the Lead in Oncology Innovations As public funding for cancer research declines, the private sector is stepping in to provide groundbreaking solutions in oncology. Key companies are at the forefront of this shift.

Facing Cuts in Public Cancer Funding, Private Sector Takes the Lead in Oncology Innovations #Canada #Vancouver #Anixa_Biosciences #Oncolytics_Biotech #ImmunityBio

FDA Grants Expanded Access for ImmunityBio’s ANKTIVA to Treat Lymphopenia, ASCO Data Show Survival Benefit in Advanced Pancreatic Cancer Company’s Cancer BioShield platform offers new hope for patients with solid tumors following standard therapy ImmunityBio (Nasdaq: IBRX) is making headline

#IBRX is in the news with FDA Expanded Access for ANKTIVA to treat lymphopenia in solid tumors. ASCO data also show improved survival in advanced pancreatic cancer, highlighting the potential of this immune-restoring therapy.
#ImmunityBio
prismmarketview.com/fda-grants-e...

ImmunityBio stock sinks after FDA issues RTF letter Investing.com -- Shares of ImmunityBio, Inc. (NASDAQ:IBRX) fell 9% following the company’s announcement that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental biologics license application (sBLA) for ANKTIVA plus Bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer (NMIBC) with papillary disease. The RTF letter was unexpected, especially considering the positive feedback and unanimous encouragement ImmunityBio received from FDA agency leaders at a January 2025 meeting. The company had been advised to submit the sBLA based on data from a single-arm trial, which showed promising results for patients with NMIBC papillary indication without carcinoma in situ (CIS). Despite this setback, ImmunityBio has already requested an urgent meeting with the FDA to address the inconsistencies between the January guidance and the RTF letter. ImmunityBio’s ANKTIVA, an interleukin-15 receptor agonist, was previously approved by the FDA in 2024 for use with BCG in treating BCG unresponsive NMIBC with papillary tumors with CIS. The recent RTF letter does not affect this prior approval but has raised concerns within the company and the medical community, given the potential benefits of the treatment for patients with papillary disease without CIS. Dr. Patrick Soon-Shiong, the Company’s Founder, Executive Chairman, and Global Chief Scientific and Medical Officer, expressed his commitment to continuing the pursuit for approval, emphasizing the strong clinical response and the five-year follow-up data supporting ANKTIVA’s potential. He also highlighted the importance of providing this treatment option to patients faced with the possibility of radical cystectomy and the progression of their disease. Dr. Rachel Sherman, former FDA Principal Deputy Commissioner, also expressed her surprise at the RTF letter, given the previous consensus at the January meeting. She urged for a rapid resolution to avoid delaying a treatment that could significantly benefit patients at high risk. The QUILT-3.032 study, which is the basis for the sBLA, is a Phase II/III trial evaluating the efficacy of ANKTIVA in combination with BCG in patients with high-grade NMIBC unresponsive to BCG treatment. The study’s data demonstrated significant disease-specific survival rates and bladder preservation in patients, which ImmunityBio hoped would support the regulatory review and approval process. ImmunityBio is seeking to clarify the FDA’s decision and expedite the review process for ANKTIVA in the NMIBC papillary indication without CIS. The company remains focused on addressing the high risk of BCG unresponsive bladder cancer and preventing disease progression. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #ImmunityBio #FDA #StockMarket #Investing #Biotech

ImmunityBio Securities Class Action Settlement: Important Updates for Investors A class action has been proposed regarding ImmunityBio, Inc. securities. Investors must be aware of their rights and the settlement process details.

ImmunityBio Securities Class Action Settlement: Important Updates for Investors #United_States #San_Diego #Class_Action #Settlement #ImmunityBio